Galvani is developing therapies to treat disease through implant-based direct modulation of specific neural signals to organs central in chronic disease. These therapies are designed to be safe, precise in their therapeutic effect, and minimally invasive in their delivery through use of small and efficient wireless electronics and keyhole surgery. Connected software will ensure that patients and physicians can effectively control and optimise the therapy.
Galvani Bioelectronics is a pioneering medical research company dedicated to the development of bioelectronic medicines to treat chronic diseases. Formed through a partnership between two global healthcare companies, GlaxoSmithKline (GSK) and Verily Life Sciences (formerly Google Life Sciences), a subsidiary of Alphabet Inc., Galvani Bioelectronics combines GSK’s life science knowledge with Verily’s expertise in software and electronics for clinical applications.
THERAPEUTIC FOCUS AREAS
|Rheumatoid Arthritis*||Bladder Dysfunction|
|Post-surgical complications*||Chronic Obstructive Pulmonary Disease (COPD)|
|Systemic Lupus Erythematosus (SLE)||Sleep Apnea|
|Psoriatic Arthritis||Type II Diabetes|
|Type 1 Diabetes|